Targeting Myeloid-derived Suppressor Cells in Tumor Immunotherapy: Current, Future and Beyond

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2023 Apr 3

PMID 37006306

Authors

Yang Zhao

Junfeng Du

Xiaofei Shen

Affiliations

Soon will be listed here.

Abstract

Myeloid-derived suppressor cells (MDSCs) are one of the major negative regulators in tumor microenvironment (TME) due to their potent immunosuppressive capacity. MDSCs are the products of myeloid progenitor abnormal differentiation in bone marrow, which inhibits the immune response mediated by T cells, natural killer cells and dendritic cells; promotes the generation of regulatory T cells and tumor-associated macrophages; drives the immune escape; and finally leads to tumor progression and metastasis. In this review, we highlight key features of MDSCs biology in TME that are being explored as potential targets for tumor immunotherapy. We discuss the therapies and approaches that aim to reprogram TME from immunosuppressive to immunostimulatory circumstance, which prevents MDSC immunosuppression activity; promotes MDSC differentiation; and impacts MDSC recruitment and abundance in tumor site. We also summarize current advances in the identification of rational combinatorial strategies to improve clinical efficacy and outcomes of cancer patients, deeply understanding and pursuing the mechanisms and characterization of MDSCs generation and suppression in TME.

Citing Articles

Metabolic crossroads: unravelling immune cell dynamics in gastrointestinal cancer drug resistance.

Suri C, Pande B, Suhasini Sahithi L, Swarnkar S, Khelkar T, Verma H Cancer Drug Resist. 2025; 8:7.

PMID: 40051496 PMC: 11883236. DOI: 10.20517/cdr.2024.164.

Expanding the horizon of CAR T cell therapy: from cancer treatment to autoimmune diseases and beyond.

Yang Z, Ha B, Wu Q, Ren F, Yin Z, Zhang H Front Immunol. 2025; 16:1544532.

PMID: 40046061 PMC: 11880241. DOI: 10.3389/fimmu.2025.1544532.

m6A RNA methylation: a pivotal regulator of tumor immunity and a promising target for cancer immunotherapy.

Chen X, Yuan Y, Zhou F, Li L, Pu J, Jiang X J Transl Med. 2025; 23(1):245.

PMID: 40022120 PMC: 11871626. DOI: 10.1186/s12967-025-06221-y.

Promising Cellular Immunotherapy for Colorectal Cancer Using Classical Dendritic Cells and Natural Killer T Cells.

Singer M, Valerin J, Zhang Z, Zhang Z, Dayyani F, Yaghmai V Cells. 2025; 14(3).

PMID: 39936958 PMC: 11817869. DOI: 10.3390/cells14030166.

Tumor secretome shapes the immune landscape during cancer progression.

Yang J, Tang S, Saba N, Shay C, Teng Y J Exp Clin Cancer Res. 2025; 44(1):47.

PMID: 39930476 PMC: 11809007. DOI: 10.1186/s13046-025-03302-0.

References

Tobin R, Jordan K, Robinson W, Davis D, Borges V, Gonzalez R . Targeting myeloid-derived suppressor cells using all-trans retinoic acid in melanoma patients treated with Ipilimumab. Int Immunopharmacol. 2018; 63:282-291. PMC: 6134177. DOI: 10.1016/j.intimp.2018.08.007. View

Sumida K, Wakita D, Narita Y, Masuko K, Terada S, Watanabe K . Anti-IL-6 receptor mAb eliminates myeloid-derived suppressor cells and inhibits tumor growth by enhancing T-cell responses. Eur J Immunol. 2012; 42(8):2060-72. DOI: 10.1002/eji.201142335. View

Ghorpade D, Holla S, Sinha A, Alagesan S, Balaji K . Nitric oxide and KLF4 protein epigenetically modify class II transactivator to repress major histocompatibility complex II expression during Mycobacterium bovis bacillus Calmette-Guerin infection. J Biol Chem. 2013; 288(28):20592-606. PMC: 3711323. DOI: 10.1074/jbc.M113.472183. View

Wu K, Lin K, Li X, Yuan X, Xu P, Ni P . Redefining Tumor-Associated Macrophage Subpopulations and Functions in the Tumor Microenvironment. Front Immunol. 2020; 11:1731. PMC: 7417513. DOI: 10.3389/fimmu.2020.01731. View

Eriksson E, Wenthe J, Irenaeus S, Loskog A, Ullenhag G . Gemcitabine reduces MDSCs, tregs and TGFβ-1 while restoring the teff/treg ratio in patients with pancreatic cancer. J Transl Med. 2016; 14(1):282. PMC: 5041438. DOI: 10.1186/s12967-016-1037-z. View

Veglia F, Tyurin V, Blasi M, De Leo A, Kossenkov A, Donthireddy L . Fatty acid transport protein 2 reprograms neutrophils in cancer. Nature. 2019; 569(7754):73-78. PMC: 6557120. DOI: 10.1038/s41586-019-1118-2. View

Poschke I, Mougiakakos D, Hansson J, Masucci G, Kiessling R . Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Res. 2010; 70(11):4335-45. DOI: 10.1158/0008-5472.CAN-09-3767. View

Sun R, Luo H, Su J, Di S, Zhou M, Shi B . Olaparib Suppresses MDSC Recruitment via SDF1α/CXCR4 Axis to Improve the Anti-tumor Efficacy of CAR-T Cells on Breast Cancer in Mice. Mol Ther. 2020; 29(1):60-74. PMC: 7791086. DOI: 10.1016/j.ymthe.2020.09.034. View

Prasad M, Zorea J, Jagadeeshan S, Shnerb A, Mathukkada S, Bouaoud J . MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer. J Immunother Cancer. 2022; 10(3). PMC: 8928405. DOI: 10.1136/jitc-2021-003917. View

10.

Lu Z, Zou J, Li S, Topper M, Tao Y, Zhang H . Epigenetic therapy inhibits metastases by disrupting premetastatic niches. Nature. 2020; 579(7798):284-290. PMC: 8765085. DOI: 10.1038/s41586-020-2054-x. View

11.

Ye C, Geng Z, Dominguez D, Chen S, Fan J, Qin L . Targeting Ornithine Decarboxylase by α-Difluoromethylornithine Inhibits Tumor Growth by Impairing Myeloid-Derived Suppressor Cells. J Immunol. 2015; 196(2):915-23. PMC: 4707077. DOI: 10.4049/jimmunol.1500729. View

12.

Li B, Luo Y, Zhou Y, Wu J, Fang Z, Li Y . Role of sanguinarine in regulating immunosuppression in a Lewis lung cancer mouse model. Int Immunopharmacol. 2022; 110:108964. DOI: 10.1016/j.intimp.2022.108964. View

13.

Porta C, Consonni F, Morlacchi S, Sangaletti S, Bleve A, Totaro M . Tumor-Derived Prostaglandin E2 Promotes p50 NF-κB-Dependent Differentiation of Monocytic MDSCs. Cancer Res. 2020; 80(13):2874-2888. DOI: 10.1158/0008-5472.CAN-19-2843. View

14.

Kim R, Hashimoto A, Markosyan N, Tyurin V, Tyurina Y, Kar G . Ferroptosis of tumour neutrophils causes immune suppression in cancer. Nature. 2022; 612(7939):338-346. PMC: 9875862. DOI: 10.1038/s41586-022-05443-0. View

15.

Liu M, Zhou J, Liu X, Feng Y, Yang W, Wu F . Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma. Gut. 2019; 69(2):365-379. DOI: 10.1136/gutjnl-2018-317257. View

16.

Bauer R, Udonta F, Wroblewski M, Ben-Batalla I, Santos I, Taverna F . Blockade of Myeloid-Derived Suppressor Cell Expansion with All- Retinoic Acid Increases the Efficacy of Antiangiogenic Therapy. Cancer Res. 2018; 78(12):3220-3232. DOI: 10.1158/0008-5472.CAN-17-3415. View

17.

Marvel D, Gabrilovich D . Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. J Clin Invest. 2015; 125(9):3356-64. PMC: 4588239. DOI: 10.1172/JCI80005. View

18.

Nakamura K, Smyth M . Myeloid immunosuppression and immune checkpoints in the tumor microenvironment. Cell Mol Immunol. 2019; 17(1):1-12. PMC: 6952382. DOI: 10.1038/s41423-019-0306-1. View

19.

Alfaro C, Teijeira A, Onate C, Perez G, Sanmamed M, Andueza M . Tumor-Produced Interleukin-8 Attracts Human Myeloid-Derived Suppressor Cells and Elicits Extrusion of Neutrophil Extracellular Traps (NETs). Clin Cancer Res. 2016; 22(15):3924-36. DOI: 10.1158/1078-0432.CCR-15-2463. View

20.

Schweizer M, Carducci M . From bevacizumab to tasquinimod: angiogenesis as a therapeutic target in prostate cancer. Cancer J. 2013; 19(1):99-106. DOI: 10.1097/PPO.0b013e31827e0b86. View